Doctor Antonio Calles

14/02/2023

🩸 Brief report: Clinical Outcomes Using Plasma-based Molecular Profiling to Guide Treatment Decisions in Patients with Advanced NSCLC and Limited Access to Broad Tissue Testing. 🎯🫁 Our recent work by now published

Next-generation sequencing (NGS) for non-small cell lung cancer (NSCLC) is becoming more widely used, but the rate of testing varies depending on the region. Plasma-based NGS is emerging as either complementary or alternative to standard tissue genotyping in metastatic non-small-cell lung cancer (NS...

14/02/2023

🦄 Osimertinib in non-exon 19 deletion or L858R EGFR mutations (excluded from FLAURA trial) Important issue, as they represent ≈ 20% of EGFR mutations in the clinic.
Thrilled to participate in this study now 🔝 as Editor’s choice

Approximately 10% of EGFR mutations (EGFRmuts) are uncommon (ucEGFRmuts). We aimed to collect real-world data about osimertinib for patients with ucEGFRmuts.

02/02/2023

¡No te pierdas la gran cita de este viernes! Bienvenidos a 🎉

Grandes profesionales como el Doctor Antonio Calles, el D. Bernard Gaspar y el Dr. Jesús Corral, nos descubrirán por primera vez las funcionalidades de esta nueva herramienta de la que todo paciente con podrá beneficiarse 👏

Sin duda, un espacio donde estar debidamente informado de todas las novedades oncológicas y con la posibilidad de acudir a ellas en el momento y lugar que tú elijas 📲

¿Aún quieres saber más? Únete a nosotros este viernes a las 18.00h 🗓️ https://www.aliacontigo.es/lanzamiento.html?cid=so_facebookpualiastreaming2301esonlc

05/06/2021

OncoAlert
Glad to share with you the COVID-19 Risk in ONcology Evaluation Tool (CORONET), lead by Dr. Becki Lee, a huge collaborative global effort including real world patient data from Co-CARE, UK, USA, and Spain.
CORONET is an online tool to support decisions regarding hospital admissions or discharge in cancer patients presenting with symptoms of COVID-19 and the likely severity of illness.
Presented at and granted with the Conquer Cancer Foundation award!
Now available in website here!

CORONET is an online tool to support decisions regarding hospital admissions or discharge in cancer patients presenting with symptoms of COVID-19 and the likely severity of illness.

22/04/2021

A ready-to-use and open-access checklist for critically appraising trials to reduce biased results in stems from an ESMO analysis on major issues that can distort the -MCBS scores.

"Lack of understanding of the various issues affecting clinical trial interpretation can lead to incorrect, although well intentioned, decisions in care." comments leading author Bishal Gyawali. Results from the analysis will be used to further fine-tune the scale which is widely used to assess the magnitude of clinical benefit of anticancer medicines

http://ow.ly/mWKb50Eve0V

ESMO is Europe’s leading medical oncology society, providing a professional network for its members and working with national societies across Europe.

04/02/2021

I am committed to care of people with and to secure best treatment for patients with .
I am committed to clinical research to improve patients’ life.
I am committed to educate professionals, patients and advocates.
I am & I will

11/07/2020

ESMO Leaders Generation Programme Alumni Members, the ESMO Social Media Working Group and the OncoAlert Network have collaborated on a survey to address the role of social media and virtual meetings during the COVID-19 pandemic.

The information gathered will help ESMO understand how these areas can be best used to disseminate information and educational materials to support the oncology community during this challenging time and in the future.

Thank you for your time and consideration.
European Society of Medical Oncology OncoAlert
ESMO - European Society for Medical Oncology

Qualtrics makes sophisticated research simple and empowers users to capture customer, product, brand & employee experience insights in one place.

01/06/2020

I am glad to see the warm welcome to our chapter published in the American Society of Clinical Oncology (ASCO) Educational Book. It is climbing among the most read articles! Wow, thank you to all the readers!!!

Immune checkpoint blockade with PD-(L)1 antibodies has revolutionized the treatment of advanced non–small cell lung cancer (NSCLC). Similarly, the identification and targeting of oncogene drivers in metastatic NSCLC has dramatically improved patient outcomes with an expanding list of potentially a...

23/05/2020

Hace justo 1 año tenía lugar el I Congreso Virtual de Médica Una iniciativa pionera en la que tuve el placer y el honor de participar. ¿Quién hubiera imaginado que en 2020 este formato se convertiría en la “nueva normalidad”?

20/05/2020

📚 Acaba de salir publicado el artículo que hemos escrito para el Libro Educacional de la Sociedad Americana de Oncología Clínica (ASCO) sobre el uso de inmunoterapia en pacientes con cáncer de pulmón con mutaciones activadoras.

'Checkpoint Blockade in Lung Cancer With Driver Mutation: Choose the Road Wisely'.

Una colaboración con la Dra. Brahmer y el Dr. Jonathan Riess.
Un auténtico privilegio la oportunidad que se me ha concedido de colaborar con la Sociedad más grande a nivel mundial contra el cáncer y que espero podáis disfrutar. El acceso es online y gratuito.
American Society of Clinical Oncology (ASCO)

Immune checkpoint blockade with PD-(L)1 antibodies has revolutionized the treatment of advanced non–small cell lung cancer (NSCLC). Similarly, the identification and targeting of oncogene drivers in metastatic NSCLC has dramatically improved patient outcomes with an expanding list of potentially a...